Investment Council: $COTY

Coty is a leveraged beauty conglomerate undergoing simultaneous leadership transition, structural segment decline, and a scheduled loss of its third-largest brand. The stock at $2.03 prices in significant distress and probability-weighted math suggests 57–69% upside — but the moat is eroding in real time, and price discipline demands waiting for evidence of stabilization before catching this knife.

The council’s moat assessment reveals a company whose brand portfolio is weakening at the structural level, even as individual prestige brands remain strong. Hugo Boss continues to perform as a top-tier prestige fragrance, with BOSS Bottled Beyond tracking as the #2 male fragrance launch in Europe. Marc Jacobs, Burberry, and Chloe each grew 30–140% from FY2019 to FY2025. The prestige engine is not broken.

But the company-level moat is eroding on three fronts. First, the Gucci fragrance license — generating an estimated $550 million in annual revenue and roughly 12.5% of total EBITDA — expires in June 2028, with L’Oreal taking over under a 50-year exclusive deal. Replacement licenses (Swarovski, Etro, Marni) are collectively modest and do not approach Gucci’s scale. Second, Consumer Beauty is in structural freefall: seven quarters of accelerating decline at -9% LFL, CoverGirl losing relevance among Gen Z, and operating income down 70%+ year-over-year. Third, and most telling, Coty’s Prestige segment is declining -5% LFL while the global prestige fragrance market grows 4–6% annually. Coty is not riding a down cycle — it is losing share in a growing market.

Gross margin compressed 250 basis points to 61.8% in Q3 FY2026, and peers like L’Oreal and Estee Lauder are strengthening their fragrance portfolios while Coty contracts. The Interparfums takeover rumor for Boss/Burberry licenses — denied by both parties — signals that the market perceives Coty’s license portfolio as vulnerable.

The stock's 62% decline from $5.34 to $2.03 tracks a clear catalyst sequence: CEO Sue Nabi's abrupt departure in December 2025 ($4.20 → $3.80), the Q2 FY2026 earnings catastrophe in February 2026 with guidance withdrawal ($3.43 → $2.66), and a continued drift to a $1.92 low in April 2026 as the securities lawsuit and Gucci uncertainty compounded.

The crisis is real — not a market overreaction. Consumer Beauty operating income collapsed 70%+ year-over-year. Full-year EBITDA guidance was cut from $1 billion to $838–848 million. A securities class action alleges concealed deterioration throughout 2025. These are not perception problems.

But the damage is bounded. Free cash flow of $276 million over nine months covers debt service. Leverage at 3.4x (seasonal peak) is elevated but not distressed. The surgical path is identifiable: divest Consumer Beauty, replace Gucci revenue partially, and re-rate as a Prestige pure-play. The gap between market fear (terminal decline and debt trap) and operating reality (intact cash generation, manageable leverage) is moderate — the fear is directionally correct but arguably over-weighted at $2.03. Second-order compounding effects exist (talent attrition, investor distrust, lawsuit overhang) but have a natural circuit-breaker if the CB divestiture executes.

Markus Strobel brings a strong pedigree — 33 years at P&G, culminating as President of Global Skin & Personal Care overseeing 12+ brands. His signature achievement was turning around SK-II from multiyear decline to Asia's #1 prestige skincare brand. He also ran P&G's prestige fragrance portfolio including Gucci, Hugo Boss, and Valentino — meaning he has direct operational familiarity with the exact license portfolio Coty now manages.

Execution in the first five months has been concrete: the Coty.Curated strategy with $200 million in FY2026 cost savings and $500 million cumulative by FY2027, a board overhaul adding five new independent directors, Citi retained for the CB strategic review, and new fragrance licenses signed. The board refresh is the strongest signal — Kunze-Concewitz tripled Campari over 16 years with 27 acquisitions, Fischer ran $4B+ at Shiseido with deep beauty M&A experience, and Plaines brings CFO-level audit expertise critical for the securities lawsuit.

The gaps, however, are significant. No permanent CEO has been named. No Gucci replacement license has been announced. The Consumer Beauty strategic review — supposedly due by fiscal year-end in June 2026 — has not produced a deal with one month remaining. Strobel's P&G playbook maps cleanly to operational turnaround, but he has never run a public company, never executed a major divestiture, and never managed a securities class action.

At 5.9x EV/EBITDA, Coty trades at the lowest multiple in its modern history — 48% of its five-year median of 12.3x. The discount to peers is extreme: 52% below Inter Parfums (its closest structural peer at 12.2x) and 70–75% below L'Oreal and Estee Lauder.

Probability-weighted scenario math supports upside. Even stress-testing TR's framework with harsher assumptions (35% bear, 45% base, 20% bull), the expected value of $3.18 implies 57% above the current price. The worst-case floor — post-Gucci EBITDA at a distressed 5x, minus debt and lawsuit settlement — is approximately $0.68 per share. The current price of $2.03 sits at 3x that floor, meaning the market is pricing something between the bear and base case, not full catastrophe. Analyst consensus sits at $3.70 across 17 analysts.

The valuation is genuinely attractive on paper. But every multiple reflects a company losing its third-largest brand in 24 months, dragging a value-destroying Consumer Beauty segment, carrying $3.2 billion in debt, and facing a securities class action — all without a permanent CEO.

The council's key tension is textbook "cheap for a reason." Three of four specialists see actionable ingredients — fixable crisis, adequate management, deeply discounted valuation — yet the Moat Auditor's ERODING verdict triggers AVOID, and the council affirms this gate as correct.

The Gucci loss is not speculative risk to be probability-weighted — it is a contractual certainty. The license transfers to L'Oreal in June 2028, removing ~$550 million in revenue and ~$100 million in EBITDA. No announced replacement comes close. Meanwhile, Prestige is underperforming its own category, suggesting the Gucci overhang may be chilling retailer and partner confidence in a negative feedback loop that cheap valuation alone cannot break.

The moat gate exists precisely for this situation. A stock can be cheap and still be an avoid if the underlying competitive position is deteriorating faster than the price decline implies. COTY may ultimately prove to be a successful turnaround — the board quality is high, the surgical path is clear, and the P&G playbook maps well. But the council requires evidence of moat stabilization, not just low multiples, before upgrading.

A Gucci replacement license with projected revenue exceeding $300 million annually from a top-20 fashion house would materially close the EBITDA gap and challenge the ERODING moat verdict. Two consecutive quarters of flat-or-positive Prestige LFL would demonstrate the core portfolio is stabilizing independent of Gucci. A Consumer Beauty divestiture at 5x+ EBITDA with proceeds applied to deleveraging below 2.5x would remove the structural drag and transform Coty into a cleaner Prestige pure-play. Any two of these three would likely flip the verdict to WAIT; all three would open BUY.

Q4 FY2026 earnings on August 6, 2026 is the critical event. Three signals matter: whether Strobel reinstates FY2027 guidance (or continues withdrawal), the Consumer Beauty strategic review outcome (sale, spin-off, or continued review), and any commentary on Gucci replacement pipeline. Insider buying patterns are the second signal — Gordon von Bretten's 83,000-share open-market purchase in March was notable, and additional buying by Strobel himself would indicate management conviction. Third, watch for a permanent CEO announcement; Strobel's continued "Interim" title is a governance overhang that limits institutional confidence.

This analysis is research, not investment advice. The TR research it's built on is at turnaroundradar.com. For all current verdicts across the portfolio, see The Verdict Board.